Compare Johnson & Johnson (JNJ) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Macy's Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Macy's Inc trades at $22.67 (market cap $5.95B). The key difference: Johnson & Johnson is far larger — about 103.9× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Macy's Inc for 58 Days on average.
| JNJ | M | |
|---|---|---|
Market Cap | $618.09B | $5.95B |
Volume | 6,050,983 | 6,030,644 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $26.21 |
52-Week Low | $186.00 | $16.51 |
Typical Hold Time | 129 Days | 58 Days |
Enterprise Value | $646.37B | $9.75B |
Dividend Yield | 2.09% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Macy's (M) trades at $22.67, down 0.53% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27, supported by a 15.99% ROE. Recent earnings have consistently beaten estimates, and the company's 'A Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has declined from 2022 peaks. Cash flow trends are improving, with net cash flow turning positive in 2024 and 2025.
The outlook is cautiously optimistic, with a consensus price target of $24.25 offering potential upside. Investment opportunities include deep value, dividend yield, and successful turnaround execution. Key risks are competitive pressures, uneven sales growth, and macroeconomic sensitivity affecting consumer spending. Analyst sentiment is mixed, with 32% buy ratings but 51% hold, reflecting uncertainty around sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
